Ensysce Biosciences, Inc. (NASDAQ: ENSC) secured over $21 million in gross proceeds during the initial closing of its Series C Preferred Stock financing on August 7, 2026. This marks a significant achievement for the company, which is pursuing a total goal of approximately $43 …
Gilead Sciences, Inc. experienced a striking contrast in its second-quarter earnings report for 2026. The company generated product sales of $7.6 billion, marking a 10% increase excluding its COVID-19 therapy, Veklury. Yet, significant investments, totaling over $11 billion in R&D, culminated in one of …
Q2 Revenue Growth Led by HIV Products
Pennon's Financial Challenges Intensify
GSK plc (LSE: GSK), a leading drug manufacturer with a marketCapitalizationof approximately $76.9 billion, has achieved regulatory approval for a chronic hepatitis B drug and a cancer therapy aimed at solid tumors. This move comes at a time when the company seeks to expand …
Chang’e-7 Postponed for Unmet Requirements
Inovio is on the verge of a critical decision from the FDA, which is poised to impact its future significantly within the biopharmaceutical environment. The FDA's judgment will potentially confirm the company's development progress and could directly affect its stock market performance. Investors are …
Diplomatic talks between Pakistan and Iran have reportedly made significant progress, which may contribute to easing long-standing tensions in the region. This development comes amid decades of strained relations, influenced by various geopolitical factors. Enhanced stability is likely to affect key sectors, including energy …
Zoetis Expands TreatmentOptionswith Simparica Trio
These new threats come amidst ongoing geopolitical strife in the region, raising concerns for shipping operators and investors alike. An uptick in vessel inspections and possible rerouting could result in increased operational costs and disruptions, makingStakeholderswary of future cargo deliveries. As conflicts escalate in …